12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Correlogic, Vermillion deal

Vermillion acquired substantially all of Correlogic's assets, which are related to its ovarian cancer diagnostics business, for $435,000 in cash. The assets include Correlogic's OvaCheck1, OvaCheck2 and Mass Spectrometer Test development-stage diagnostics for detecting ovarian cancer, over 1,000 diagnostic samples from ovarian cancer studies, three biomarker-related U.S. patents and software. Vermillion will use the assets to develop OVA2, a next-generation ovarian cancer...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >